flasco.orgFLASCO / The Voice of Oncology in Florida

`` Diversity and Inclusion in Cancer Health Equity Florida Society of Clinical Oncology The Voice of Oncology in Florida Menu Flasco Patient Portal Become a Member FLASCO Meetings Search the Florida Society of Clinical Oncology Website SEARCH Menu Home About Profile & Mission History Board of Directors & Liaisons Committees A Year in Review FLASCO Staff FLASCO Oncology Captains Membership Benefits Become a Member Become a Corporate Partner Professional Partnership Program Corporate Partners Events Calendar of Events FLASCO Events Events Webinars Past Events Advocacy Find Your Legislator News & Updates Administrator Network Updates Clinical Trials Drugs FLASCO News FLASCO eNewsletter Legislative Updates Member Publications For Professionals Professional Associations Resources Podcasts Job Board Contact THE VOICE OF ONCOLOGY IN FLORIDA FLASCO is a member supported state society that focuses on providing education, advocacy, communication and general support of the Florida professionals who have chosen the challenging medical discipline of oncology. UPCOMING EVENTS CORPORATE MEMBERSHIP BENEFITS BENEFITS FOR ONCOLOGY PROFESSIONALS Latest News & Updates Latest News Drug Updates New Cervical Cancer Guidelines Released March 26, 2024 The American Society for Colposcopy and Cervical Pathology (ASCCP) is proud to announce a major milestone by the groundbreaking Enduring Guidelines initiative, aimed at revolutionizing the fight against cervical cancer. In a bid to ensure the most current and effective clinical management strategies, the Enduring Guidelines process seeks to integrate emerging technologies and the latest… Continue Reading » Judge Grants Biden Administration Motion to Dismiss Legal Challenge from PhRMA February 26, 2024 On February 11, a federal judge dismissed a drug industry trade group’s legal challenge to halt Medicare drug price negotiations, ruling that it lacked standing. The complaint was filed by the Pharmaceutical Research and Manufacturers of America (PhRMA), the Global Colon Cancer Association (GCCA), and the National Infusion Center Association (NICA) in June of last… Continue Reading » Session Midpoint Report: What Physicians Should Know February 21, 2024 February 14, 2024 marked day 30 of the 60-day Florida Legislative Session, and the FMA remains hard at work to help physicians practice medicine. This midpoint report by FMA Assistant General Counsel Mary Thomas, Esq., summarizes some of the most notable bills that could affect you and your patients, where each one stands in the… Continue Reading » 2024 MEDPARD Available Now! February 21, 2024 The 2024 Medicare Participation Physicians / Suppliers Directory (MEDPARD) is now available. As in the past, there will be no hardcopy distributions. Beneficiaries can use the Physician Compare website or contact 1-800-MEDICARE for assistance in locating a participating supplier near their home. Continue Reading » FDA approves tisotumab vedotin-tftv for recurrent or metastatic cervical cancer April 29, 2024 On April 29, 2024, the Food and Drug Administration granted traditional approval to tisotumab vedotin-tftv (Tivdak, Seagen Inc. [now a part of Pfizer Inc.]) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication. Continue Reading » FDA grants accelerated approval to tovorafenib for patients with relapsed or refractory BRAF-altered pediatric low-grade glioma April 23, 2024 On April 23, 2024, the Food and Drug Administration granted accelerated approval to tovorafenib (Ojemda, Day One Biopharmaceuticals, Inc.) for patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. Continue Reading » FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS April 23, 2024 On April 23, 2024, the Food and Drug Administration approved lutetium Lu 177 dotatate (Lutathera, Advanced Accelerator Applications USA, Inc., a Novartis company) for pediatric patients 12 years and older with somatostatin receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. Lutetium Lu 177 dotatate received approvalExternal Link Disclaimer for this… Continue Reading » FDA approves nogapendekin alfa inbakicept-pmln for BCG-unresponsive non-muscle invasive bladder cancer April 22, 2024 On April 22, 2024, the Food and Drug Administration approved nogapendekin alfa inbakicept-pmln (Anktiva, Altor BioScience, LLC) with Bacillus Calmette-Guérin (BCG) for adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. Continue Reading » Video Highlights Nursing App Pharmacy Multi Disciplinary Get More from FLASCO With Your Partnership The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together. Contact Flasco to Discuss Partnership View Full Directory of Corporate Partners Corporate Partners Diamond Elite Diamond Platinum Gold Upcoming Events Click to view full events calendar . May 17, 2024 Great Strides Together 2024 May 18, 2024 Rapid Integrations Training Program May 25, 2024 7:30 am Veterans Living With Cancer We’re Here to Help Contact Us Add your name, email & message below: Name * Email * Phone Subject Message What goes up, must come Important Links About FLASCO Photo Gallery Membership Advocacy Contact FLASCO User Links FLASCO Patient Portal Become a Member Refund Policy Privacy Policy Security Disclaimer © 2021 FLASCO | Premium Website Design by The HDG FLASCO Home About Profile & Mission History Board of Directors & Liaisons Committees A Year in Review FLASCO Staff FLASCO Oncology Captains Back Membership Benefits Become a Member Become a Corporate Partner Professional Partnership Program Corporate Partners Back Events Calendar of Events FLASCO Events Events Webinars Past Events Back Advocacy Find Your Legislator Back News & Updates Administrator Network Updates Clinical Trials Drugs FLASCO News FLASCO eNewsletter Legislative Updates Member Publications Back For Professionals Professional Associations Resources Podcasts Job Board Back Contact Flasco Patient Portal Become a Member FLASCO Meetings × Close...